Development and validation of HPLC-DAD method of determination piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate in 1 % solution
DOI:
https://doi.org/10.14739/2310-1210.2017.6.115313Keywords:
triazoles, high pressure liquid chromatography, pharmaceutical products, veterinary drugsAbstract
Purpose. The purpose of this research is to develop new, highly sensitive and selective method for determination of piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate as an active pharmaceutical ingredient (API) in 1 % injection solution based on high performance liquid chromatography with diode-array detection.
Materials and methods. LC System was Agilent 1260 Infinity (degasser, binary pump, autosampler, thermostatted column compartment, diode array detector). Single quadrupole mass spectrometer Agilent 6120 with ionization in electrospray (ESI). Open LAB CDS Software. Column was Zorbax SB-C18; 30 mm × 4.6 mm; 1.8 µm. Injection volume was 2 µL. Isocratic mode. The mobile phase was water/acetonitrile (70:30) with 0.1 % methanoate acid. Standard samples were piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate, furan-2-carbohydrazide, 2-(furan-2-carbonyl)-N-phenylhydrazine-1-carbothioamide, 5-(furan-2-yl)-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione.
Results. The graphs of the capacity factor from the acetonitrile concentration dependence in the mobile phase for potential impurities and API on diode-array detector were constructed. Optimal chromatography separation conditions for impurities and API were proposed. The UV spectra of API and impurities were presented. The API peak purity by mass spectrometric detector was determined. Method of the quantitative determination of the API in 1 % solution for injection was elaborated. Total sample preparation uncertainty was predicted. Method was validated according to European and Ukrainian Pharmacopeia. It was applied for real samples solutions for injection.
Conclusions. The chromatography separation conditions of impurities and piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate were studied The method of determination of piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate in 1 % solution for injection was elaborated.
The results of the method validation show that it is specific and meet the requirements of linearity, precision and accuracy.
References
Parchenko, V. V., Panasenko, O. I., Knysh, E. G., Vasiuk, S. O., & Tarkhanova, O. O. (2009). Yakisne ta kilkisne vyznachennia piperydynii 2-[5-(furan-2-il)-4-fenil-1, 2, 4-tryazol-3-iltio] atsetatu 1% ta 2,5% rozchynakh [Qualitative and quantitative determination of the Piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate 1% and 2,5% solutions]. Zaporozhye medical journal, 3, 111–112. [in Ukrainian].
Parchenko, V. V., Panasenko, O. I., Knysh, E. G., Vasyuk S. O., & Tarkhanova, O. O. (2009). Rozrobka metodyky kilkisnoho vyznachennia piperydyniiu 2-[5-(furan-2-il)-4-fenil-1,2,4- tryazol-3-iltio] atsetatu v substantsii [Working out of methods quantitative determination piperidiniy 2-[5-(furan-2-il)-4-phenil-1,2,4-triazol-3-ilthio]acetate in the substance]. Ukrainskyi biofarmatsevtychnyi zhurnal, 4, 44–45. [in Ukrainian].
(2008) Derzhavna Farmakopeia Ukrainy. Dopovnennia 2. [The State Pharmacopoeia of Ukraine. Supplement 2]. Kharkiv: RІREH. [in Ukrainian].
Parchenko, V.V. (2006). Syntez, fizyko-khimichni ta biolohichni vlastyvosti pokhidnykh 1,2,4-triazol-3-tionu, yaki mistyat' yadro furanu (Dis… kand. farm. nauk). [Synthesis, physicochemical and biological properties of derivatives of 1,2,4-triazoles-3-thione containing core furan. Dr. farm. sci. diss.]. Zaporizhzhia [in Ukrainian].
Varynskyj, B. O. (2015) Doslidzhennia kharkterystyk utrymuvannia riadu hidrazydiv karbonovykh kyslot i hidrazynokabotioamidiv, vykhidnykh rechovyn pry syntezi substantsii dlia vyhotovlennia likarskykh zasobiv metodom VERKh-UF-ESI-MS [Study retention characteristics of series hydrazides of carboxylic acids and hydrazynocabothioamids, starting materials in the synthesis of bulk drugs for manufacturing of the pharmaceutical preparations by HPLC-UV-ESI-MS]. Problemy viiskovoi okhorony zdorovia. Zbirnyk naukovykh prats Ukrainskoi viiskovo-medychnoi akademii, 43, 320–330. [in Ukrainian].
Varynskyi, B. O., Knysh, Ye. G., Parchenko, V. V., Pаnаsenkо, O. І. & Kаplаushenkо, A. G. (2015) Vyvchennia zakonomirnostei utrymuvannia potentsiinykh likarskykh substantsii riadu 1,2,4-triazol-3-iltioatsetatnykh kyslot ta yikh solei metodom VERKh / DMD-MS [The study of retention regularities for the potential drug substances of 1,2,4-triazol-3-ylthioacetic acids and their salts series by the method of HPLC/DAD-MS]. Zhurnal orhanichnoi ta farmatsevtychnoi khimii, 4, 68–72. [in Ukrainian].
Varynskyi, B. O. (2016) Vyvchennia metodom VERKh-DMD-MS zakonomirnostei utrymuvannia riadu 1,2,4-triazol-3-tioniv – napivproduktiv v syntezi aktyvnykh farmatsevtychnykh inhrediientiv [Study by HPLC-DAD-MS retention regularities of the 1,2,4-triazoles-3-tione series – intermediate materials in the synthesis of active pharmaceutical ingredients for medicine manufacture]. Farmakom, 1, 32–40. [in Ukrainian].
(2001) Derzhavna Farmakopeia Ukrainy [The State Pharmacopoeia of Ukraine]. Kharkiv: RІREH. [in Ukrainian].
(2013). European Pharmacopoeia. Strasbourg, France: Council of Europe.
(2004). Derzhavna Farmakopeia Ukrainy. Dopovnennia 1. [The State Pharmacopoeia of Ukraine. Supplement 1]. Kharkiv: RІREH. [in Ukrainian].
Grizodub, A. I. (2011) Standartizovannye procedury validacii metodik kontrolya kachestva lekarstvennykh sredstv [Standardized validation procedures for method of medicines quality control]. Analiticheskaya khimiya v sozdanii, standartizacii y kontrole kachestva lekarstvennykh sredstv, V. P. Georgievskogo (Ed.), (Vol. 3). Kharkiv, pp. 934–1063. [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)